Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00266656
Recruitment Status : Completed
First Posted : December 19, 2005
Results First Posted : August 23, 2016
Last Update Posted : March 31, 2017
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is an extension study that will gather long-term data on the effect of early growth hormone (GH) treatment on adult height and other aspects of health and development in girls with Turner syndrome. The main purpose is to determine whether girls who received 2 years of GH treatment before 6 years of age achieve taller adult height than girls who were untreated during this time. The study will also look at middle ear and hearing function, and cognitive and behavioral development. Protocol completion is defined as attainment of height velocity less than or equal to 1.0 cm/year, or bone age greater than or equal to 15 years.

Condition or disease Intervention/treatment Phase
Turner Syndrome Drug: Humatrope Phase 4

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 69 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Early Growth Hormone Treatment on Long-term Growth and Skeletal Maturation in Girls With Turner Syndrome
Study Start Date : December 2005
Actual Primary Completion Date : September 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Experimental 1 Control

No drug administration in B9R-US-GDFG (NCT00406926).

Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.

 Drug: Humatrope
According to investigator's clinical practice and guided by the approved package insert
Other Names:
  • LY137998
  • Somatropin
  • Growth hormone
Experimental: Experimental 2 Humatrope
Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.
 Drug: Humatrope
According to investigator's clinical practice and guided by the approved package insert
Other Names:
  • LY137998
  • Somatropin
  • Growth hormone


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Most Mature Height Standard Deviation Score (SDS) [ Time Frame: Baseline through End of Study (10 years) ]
    SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.


Secondary Outcome Measures :
  1. Height SDS at Various Ages [ Time Frame: Age 10, Age 13, Age 16 ]
    SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.

  2. Age at Attainment of Tanner 2 Breast Development [ Time Frame: Baseline through End of Study (10 years) ]
    The Tanner 2 breast development is the age at first evidence of breast development.

  3. Chronological Age at First Visit Participant Attained Bone Age of 14.5 Years [ Time Frame: Baseline through End of Study (10 years) ]
    Bone age was measured by standard radiograph, x-ray at baseline and annually for 10 years or until attainment of height velocity less than or equal to 1.0 centimeter per year (cm/year) and bone age greater or equal to 15 years.

  4. Reports of Serious Adverse Events [ Time Frame: Baseline through End of Study (10 years) ]

    Number of serious adverse events (SAEs) reported. Any adverse event from this study that results in one of the following outcomes, or is significant for any other reason were reported as an SAE: death, initial or prolonged inpatient hospitalization, a life-threatening experience (that is, immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a study subject, significant for any other reason (includes cancer, other than superficial, and basal cell or squamous cell carcinomas of the skin, that did not meet other serious adverse event criteria).

    A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.


  5. Percentage of Participants With Occurrence of Pre-specified Clinically Relevant Events [ Time Frame: Baseline through End of Study (10 years) ]
    Percentage of participants for whom certain non-serious, pre-specified adverse events (AEs; those that are commonly observed in Turner syndrome or are known to be related to GH treatment: impaired glucose tolerance, diabetes mellitus, hypothyroidism, benign intracranial hypertension, scoliosis, slipped capital femoral epiphysis, solid tumor/leukemia, pancreatitis, ear infections, and high blood pressure) are reported.

  6. Percentage of Participants With Abnormal Tympanometry Results [ Time Frame: Baseline, Age 10, Age 16, End of Study (10 years) ]
    Percentage of participants with abnormal tympanometry [defined as middle ear dysfunction / middle ear effusion / patent pressure equalizer tube or possible tympanic membrane perforation] results at baseline, age 10 years, and age 16 years or endpoint.

  7. Percentage of Participants With Prevalence of Abnormal Audiometry Results [ Time Frame: Baseline, Age 10, Age 16, End of Study (10 years) ]
    Percentage of participants with abnormal Audiometry results at baseline, age 10 years, and age 16 years or endpoint. Prevalence was calculated as number of participants with abnormal hearing divided by number of participants with measurable pure tone audiometry results at that visit.

  8. Percentage of Participants With Abnormal Audiometry Results Based on Pure Tone Average (PTA) [ Time Frame: Baseline, Age 10, Age 16, End of Study (10 years) ]
    Percentage of participants with abnormal Audiometry results at baseline, age 10 years, and age 16 years or endpoint. PTA is defined as the average of pure tone hearing thresholds at 500, 1000 and 2000 Hz (Hertz), calculated separately for each ear and for each testing method (air or bone); normal PTA is defined as pure tone hearing threshold less than or equal to 20 dB HL (decibels Hearing Level), and abnormal PTA is defined as pure tone hearing threshold greater than 20 DB HL.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Previously randomized in study B9R-US-GDFG (NCT00406926)
  • Karyotype-proven Turner syndrome

Exclusion Criteria:

  • Immediate family members of study site personnel directly affiliated with the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00266656


Locations
Layout table for location information
United States, California
Childrens Hospital of Los Angeles
Los Angeles, California, United States, 90027
United States, Colorado
Children's Hospital
Aurora, Colorado, United States, 80045
United States, Connecticut
Connecticut Children's Medical Center
Hartford, Connecticut, United States, 06106
United States, Illinois
Children's Hospital of Chicago Research Center
Chicago, Illinois, United States, 60611
United States, Indiana
Riley Hosptial for Children
Indianapolis, Indiana, United States, 46202
United States, Missouri
Children's Mercy Hospital
Kansas City, Missouri, United States, 64108
United States, North Carolina
University of NC at Chapel Hill School of Medicine
Chapel Hill, North Carolina, United States, 27514
United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
United States, Washington
Childrens Hospital and Medical Center
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hrs) Eli Lilly and Company
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00266656    
Other Study ID Numbers: 10088
B9R-US-GDGH ( Other Identifier: Eli Lilly and Company )
First Posted: December 19, 2005    Key Record Dates
Results First Posted: August 23, 2016
Last Update Posted: March 31, 2017
Last Verified: March 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Turner Syndrome
Gonadal Dysgenesis
Syndrome
Disease
Pathologic Processes
Disorders of Sex Development
Urogenital Abnormalities
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
 Heart Diseases
Congenital Abnormalities
Sex Chromosome Disorders
Chromosome Disorders
Genetic Diseases, Inborn
Gonadal Disorders
Endocrine System Diseases
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs